title: [Synthetic cannabinoids: A new addiction matrix].
abstract: Synthetic cannabinoids (SC) belong to the emergent market of new psychoactive substances, sold on the Internet or specialized shops. Since the 1970s, more than 160 new SC have invaded the drug market. These substances imitate the psychoactive effects of cannabis. Underestimated for too long, SC's market growth and consequences are no longer to be ignored, first of all in terms of public health. SC were first synthesized during researches on the endocannabinoid system. Though they are agonists of the cannabinoid receptors 1 and 2, as Δ9-tetrahydrocannabinol in cannabis, they can also have a really high affinity with these receptors, rising up their potency. Each country in the world has chosen various ways how to deal with SC: scheduling, blanket ban, regulation… In order to contour the legal system, producers regularly modify the chemical formulas of those substances and hand out an attracting packaging looking harmless. However, the content of those small packets is extremely unstable and unreliable, including harmful compounds to health. Reports show an increasing number of non-fatal intoxications but also fatalities. Consequences on the body are numerous but there have been also reports of mental health imbalance and appearances of addiction-linked clinical signs. This review of literature aims at establishing a picture on SC in order to raise awareness among professionals in the health field on this new addiction matrix.
authors.affiliation: Université Paris Sud, AP-HP, hôpital Paul-Brousse, département d'addictologie, 94800 Villejuif, France. Electronic address: amscoc@gmail.com.
authors.forename: Amandine
authors.initials: A
authors.lastname: Scocard
authors.affiliation: Université Paris Sud, AP-HP, hôpital Paul-Brousse, département d'addictologie, 94800 Villejuif, France.
authors.forename: Amine
authors.initials: A
authors.lastname: Benyamina
authors.affiliation: Université Paris Sud, AP-HP, hôpital Paul-Brousse, département d'addictologie, 94800 Villejuif, France.
authors.forename: Sarah
authors.initials: S
authors.lastname: Coscas
authors.affiliation: Inserm U1000, université Paris Sud, AP-HP, hôpital Paul-Brousse, département d'addictologie, 94800 Villejuif, France.
authors.forename: Laurent
authors.initials: L
authors.lastname: Karila
mesh_terms: D016739:Behavior, Addictive / Q000453:epidemiology*; D002186:Cannabinoids / Q000009:adverse effects / Q000737:chemistry / Q000633:toxicity; D006801:Humans; D013287:Illicit Drugs / Q000009:adverse effects / Q000737:chemistry / Q000331:legislation & jurisprudence; D043884:Receptor, Cannabinoid, CB1 / Q000819:agonists; D043885:Receptor, Cannabinoid, CB2 / Q000819:agonists; D019966:Substance-Related Disorders / Q000453:epidemiology*
chemical_list: D002186:Cannabinoids; D013287:Illicit Drugs; D043884:Receptor, Cannabinoid, CB1; D043885:Receptor, Cannabinoid, CB2